Literature DB >> 21498667

HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.

Philippa C Matthews1, Emily Adland, Jennifer Listgarten, Alasdair Leslie, Nompumelelo Mkhwanazi, Jonathan M Carlson, Mikkel Harndahl, Anette Stryhn, Rebecca P Payne, Anthony Ogwu, Kuan-Hsiang Gary Huang, John Frater, Paolo Paioni, Henrik Kloverpris, Pieter Jooste, Dominique Goedhals, Cloete van Vuuren, Dewald Steyn, Lynn Riddell, Fabian Chen, Graz Luzzi, Thambiah Balachandran, Thumbi Ndung'u, Søren Buus, Mary Carrington, Roger Shapiro, David Heckerman, Philip J R Goulder.   

Abstract

The potential contribution of HLA-A alleles to viremic control in chronic HIV type 1 (HIV-1) infection has been relatively understudied compared with HLA-B. In these studies, we show that HLA-A*7401 is associated with favorable viremic control in extended southern African cohorts of >2100 C-clade-infected subjects. We present evidence that HLA-A*7401 operates an effect that is independent of HLA-B*5703, with which it is in linkage disequilibrium in some populations, to mediate lowered viremia. We describe a novel statistical approach to detecting additive effects between class I alleles in control of HIV-1 disease, highlighting improved viremic control in subjects with HLA-A*7401 combined with HLA-B*57. In common with HLA-B alleles that are associated with effective control of viremia, HLA-A*7401 presents highly targeted epitopes in several proteins, including Gag, Pol, Rev, and Nef, of which the Gag epitopes appear immunodominant. We identify eight novel putative HLA-A*7401-restricted epitopes, of which three have been defined to the optimal epitope. In common with HLA-B alleles linked with slow progression, viremic control through an HLA-A*7401-restricted response appears to be associated with the selection of escape mutants within Gag epitopes that reduce viral replicative capacity. These studies highlight the potentially important contribution of an HLA-A allele to immune control of HIV infection, which may have been concealed by a stronger effect mediated by an HLA-B allele with which it is in linkage disequilibrium. In addition, these studies identify a factor contributing to different HIV disease outcomes in individuals expressing HLA-B*5703.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498667      PMCID: PMC3738002          DOI: 10.4049/jimmunol.1003711

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania.

Authors:  Rebecca N Koehler; Anne M Walsh; Elmar Saathoff; Sodsai Tovanabutra; Miguel A Arroyo; Jeffery R Currier; Leonard Maboko; Michael Hoelscher; Michael Hoelsher; Merlin L Robb; Nelson L Michael; Francine E McCutchan; Jerome H Kim; Gustavo H Kijak
Journal:  J Infect Dis       Date:  2010-10-05       Impact factor: 5.226

2.  PyPop update--a software pipeline for large-scale multilocus population genomics.

Authors:  A K Lancaster; R M Single; O D Solberg; M P Nelson; G Thomson
Journal:  Tissue Antigens       Date:  2007-04

3.  Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Authors:  Photini Kiepiela; Alasdair J Leslie; Isobella Honeyborne; Danni Ramduth; Christina Thobakgale; Senica Chetty; Prinisha Rathnavalu; Corey Moore; Katja J Pfafferott; Louise Hilton; Peter Zimbwa; Sarah Moore; Todd Allen; Christian Brander; Marylyn M Addo; Marcus Altfeld; Ian James; Simon Mallal; Michael Bunce; Linda D Barber; James Szinger; Cheryl Day; Paul Klenerman; James Mullins; Bette Korber; Hoosen M Coovadia; Bruce D Walker; Philip J R Goulder
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

4.  Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles.

Authors:  Hendrik Streeck; Mathias Lichterfeld; Galit Alter; Angela Meier; Nickolas Teigen; Bader Yassine-Diab; Harlyn K Sidhu; Susan Little; Anthony Kelleher; Jean-Pierre Routy; Eric S Rosenberg; Rafick-Pierre Sekaly; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

5.  HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection.

Authors:  Galit Alter; Suzannah Rihn; Katharine Walter; Anne Nolting; Maureen Martin; Eric S Rosenberg; Jeffrey S Miller; Mary Carrington; Marcus Altfeld
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

6.  Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point.

Authors:  Clive M Gray; Mandla Mlotshwa; Catherine Riou; Tiyani Mathebula; Debra de Assis Rosa; Tumelo Mashishi; Cathal Seoighe; Nobubelo Ngandu; Francois van Loggerenberg; Lynn Morris; Koleka Mlisana; Carolyn Williamson; Salim Abdool Karim
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

7.  The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection.

Authors:  A Cozzi Lepri; T L Katzenstein; H Ullum; A N Phillips; P Skinhøj; J Gerstoft; B K Pedersen
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

8.  Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection.

Authors:  Hayley Crawford; Julia G Prado; Alasdair Leslie; Stéphane Hué; Isobella Honeyborne; Sharon Reddy; Mary van der Stok; Zenele Mncube; Christian Brander; Christine Rousseau; James I Mullins; Richard Kaslow; Paul Goepfert; Susan Allen; Eric Hunter; Joseph Mulenga; Photini Kiepiela; Bruce D Walker; Philip J R Goulder
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

9.  Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes.

Authors:  Isobella Honeyborne; Andrew Prendergast; Florencia Pereyra; Alasdair Leslie; Hayley Crawford; Rebecca Payne; Shabashini Reddy; Karen Bishop; Eshia Moodley; Kriebashnie Nair; Mary van der Stok; Noel McCarthy; Christine M Rousseau; Marylyn Addo; James I Mullins; Christian Brander; Photini Kiepiela; Bruce D Walker; Philip J R Goulder
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

10.  A whole-genome association study of major determinants for host control of HIV-1.

Authors:  Jacques Fellay; Kevin V Shianna; Dongliang Ge; Sara Colombo; Bruno Ledergerber; Mike Weale; Kunlin Zhang; Curtis Gumbs; Antonella Castagna; Andrea Cossarizza; Alessandro Cozzi-Lepri; Andrea De Luca; Philippa Easterbrook; Patrick Francioli; Simon Mallal; Javier Martinez-Picado; José M Miro; Niels Obel; Jason P Smith; Josiane Wyniger; Patrick Descombes; Stylianos E Antonarakis; Norman L Letvin; Andrew J McMichael; Barton F Haynes; Amalio Telenti; David B Goldstein
Journal:  Science       Date:  2007-07-19       Impact factor: 47.728

View more
  36 in total

1.  Impact of HLA-B*52:01-Driven Escape Mutations on Viral Replicative Capacity.

Authors:  Ming-Han Chloe Tsai; Supriya Singh; Emily Adland; Philip Goulder
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection.

Authors:  Ling Yue; Heather A Prentice; Paul Farmer; Wei Song; Dongning He; Shabir Lakhi; Paul Goepfert; Jill Gilmour; Susan Allen; Jianming Tang; Richard A Kaslow; Eric Hunter
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

Review 3.  HIV and HLA class I: an evolving relationship.

Authors:  Philip J R Goulder; Bruce D Walker
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

4.  Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.

Authors:  Jonathan M Carlson; Chanson J Brumme; Eric Martin; Jennifer Listgarten; Mark A Brockman; Anh Q Le; Celia K S Chui; Laura A Cotton; David J H F Knapp; Sharon A Riddler; Richard Haubrich; George Nelson; Nico Pfeifer; Charles E Deziel; David Heckerman; Richard Apps; Mary Carrington; Simon Mallal; P Richard Harrigan; Mina John; Zabrina L Brumme
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

5.  CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.

Authors:  Catherine K Koofhethile; Zaza M Ndhlovu; Christina Thobakgale-Tshabalala; Julia G Prado; Nasreen Ismail; Zenele Mncube; Lungile Mkhize; Mary van der Stok; Nonhlanhla Yende; Bruce D Walker; Philip J R Goulder; Thumbi Ndung'u
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

6.  Immune-mediated attenuation of HIV-1.

Authors:  Denis R Chopera; Jaclyn K Wright; Mark A Brockman; Zabrina L Brumme
Journal:  Future Virol       Date:  2011-08       Impact factor: 1.831

7.  Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations.

Authors:  Howard W Wiener; Sadeep Shrestha; Hailin Lu; Etienne Karita; William Kilembe; Susan Allen; Eric Hunter; Paul A Goepfert; Jianming Tang
Journal:  Hum Immunol       Date:  2017-12-28       Impact factor: 2.850

8.  HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control.

Authors:  Henrik N Kloverpris; Anette Stryhn; Mikkel Harndahl; Mary van der Stok; Rebecca P Payne; Philippa C Matthews; Fabian Chen; Lynn Riddell; Bruce D Walker; Thumbi Ndung'u; Søren Buus; Philip Goulder
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

9.  HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race?

Authors:  Heather A Prentice; Travis R Porter; Matthew A Price; Emmanuel Cormier; Dongning He; Paul K Farmer; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

10.  HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Authors:  Julia A Sung; Shabnum Patel; Matthew L Clohosey; Lauren Roesch; Tamara Tripic; JoAnn D Kuruc; Nancie Archin; Patrick J Hanley; C Russell Cruz; Nilu Goonetilleke; Joseph J Eron; Clio M Rooney; Cynthia L Gay; Catherine M Bollard; David M Margolis
Journal:  Mol Ther       Date:  2018-09-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.